The company recently announced a partnership with Pfizer to offer its menopause hormone therapies at low prices in retail ...

GoodRx works with over 150 brands across pharmaceutical ... The company recently announced a partnership with ARS Pharmaceuticals to offer neffy at an exclusive low discounted cash price in ...

Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...

Three independent pharmacies have filed separate lawsuits accusing GoodRx, which markets a prescription drug discount card, of conspiring with several pharmacy benefit managers to fix ...

GoodRx management will also hold a conference ... Inc. ("ARS Pharmaceuticals") to offer the lowest discounted cash price for neffy® in retail pharmacy locations. Available for purchase in-store ...

Shares of NASDAQ GDRX opened at $4.70 on Monday. GoodRx has a 1 year low of $4.63 and a 1 year high of $9.26. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ...

Analyst Charles Rhyee from TD Cowen maintained a Buy rating on GoodRx Holdings (GDRX – Research Report) and decreased the price target to $10.00 from $16.00. Charles Rhyee’s rating is based on ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Hold rating on GoodRx Holdings (GDRX – Research Report). The associated price target was lowered to $7.00. Craig Hettenbach’s ...

medical device companies and OTC medicines to surface their savings and patient support programs directly with high-intent audiences via the GoodRx platform. The company recently announced a ...